RxDoctor Payments DataLook up a doctor →

Yessar Hussain, MD

Neuromuscular Medicine · Austin, TXNPI 1982852166

Payments from drug & device makers

$6,489,635in general payments, 2019–2025

Across 1,595 payments — averaging $4068.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$1.7M
  • UCB SA$1.2M
  • Alnylam Pharmaceuticals Inc.$597K
  • Regeneron$453K
  • Amgen$398K
  • Biogen$345K
  • plus $1.9M from 34 others
$280,347in research payments, 2019–2025

Across 73 payments — averaging $3840.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$219K
  • Regeneron$32K
  • Takeda Pharmaceuticals U.S.A., Inc.$20K
  • UCB, Inc.$7K
  • Sarepta Therapeutics, Inc.$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few neuromuscular medicine providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,718,974
Medicare patients
603
Services billed
33,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neuromuscular medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →